Showing 190 results
- https://www.novartis.com/news/european-commission-ec-adopts-decision-endorsing-chmp-recommendation-revoke-conditional-marketing-authorization-adakveo-crizanlizumab
- https://www.novartis.com/news/novartis-statement-collaboration-and-license-agreement-tislelizumab-beigene-ltd
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
- https://www.novartis.com/news/novartis-completes-fda-filing-approval-millburn-facility-support-pluvicto-launch
- https://www.novartis.com/news/novartis-unwavering-support-one-year-from-start-war-ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.
- https://www.novartis.com/news/novartis-statement-filing-inflation-reduction-act-lawsuit
- https://www.novartis.com/news/novartis-condemns-terrorist-actions-against-people-israel-and-loss-innocent-lives
- https://www.novartis.com/news/novartis-financial-results-q3-2023
- https://www.novartis.com/news/novartis-provides-support-moroccan-earthquake-victims
- https://www.novartis.com/news/novartis-giving-volunteering-wins-accps-2023-corporate-social-impact-team-year-award
- https://www.novartis.com/news/gt005-ppy988-development-program-geographic-atrophy
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 19
- › Next page